<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T04:40:16Z</responseDate>
  <request identifier="oai:figshare.com:article/34027379" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34027379</identifier>
        <datestamp>2026-09-29T19:05:27Z</datestamp>
        <setSpec>category_4</setSpec>
        <setSpec>category_7</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_14</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>category_133</setSpec>
        <setSpec>portal_63</setSpec>
        <setSpec>item_type_6</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Bifunctional
Nanozymes for Synergistic Treatment by
Boosting Oxidative Stress and Regulating the Protein Kinase B Pathway</dc:title>
          <dc:creator>Qi Fang (199280)</dc:creator>
          <dc:creator>Xiaojun Zhang (178074)</dc:creator>
          <dc:creator>Chong-Bo Ma (2195002)</dc:creator>
          <dc:creator>Quanyi Liu (11502591)</dc:creator>
          <dc:creator>Jingyuan Yu (15197077)</dc:creator>
          <dc:creator>Jiaqi Li (220961)</dc:creator>
          <dc:creator>Hao Sun (14095)</dc:creator>
          <dc:creator>Jicheng Ma (25138640)</dc:creator>
          <dc:creator>Hui Wei (126971)</dc:creator>
          <dc:creator>Yan Du (229593)</dc:creator>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Molecular Biology</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Plant Biology</dc:subject>
          <dc:subject>weaken antioxidant defenses</dc:subject>
          <dc:subject>responsive catalytic conversion</dc:subject>
          <dc:subject>reactive oxygen species</dc:subject>
          <dc:subject>protein kinase b</dc:subject>
          <dc:subject>minimizing adverse effects</dc:subject>
          <dc:subject>functionalized formulation ap</dc:subject>
          <dc:subject>endogenous hydrogen peroxide</dc:subject>
          <dc:subject>boosting oxidative stress</dc:subject>
          <dc:subject>boosting chemotherapeutic efficacy</dc:subject>
          <dc:subject>pod )- like</dc:subject>
          <dc:subject>suppresses tumor growth</dc:subject>
          <dc:subject>molecule akt inhibitors</dc:subject>
          <dc:subject>conventional akt inhibitors</dc:subject>
          <dc:subject>2 &lt;/ sub</dc:subject>
          <dc:subject>like activities</dc:subject>
          <dc:subject>synergistic treatment</dc:subject>
          <dc:subject>sequencing analysis</dc:subject>
          <dc:subject>safer alternative</dc:subject>
          <dc:subject>related signaling</dc:subject>
          <dc:subject>precise inhibition</dc:subject>
          <dc:subject>muc1 aptamer</dc:subject>
          <dc:subject>largely driven</dc:subject>
          <dc:subject>generalizable approach</dc:subject>
          <dc:subject>enhance chemosensitivity</dc:subject>
          <dc:subject>bifunctional nanozymes</dc:subject>
          <dc:subject>although small</dc:subject>
          <dc:subject>akt phosphorylation</dc:subject>
          <dc:subject>adr models</dc:subject>
          <dc:subject>aberrant activation</dc:subject>
          <dc:description>Chemoresistance
and dose-limiting toxicity remain major challenges
in cancer chemotherapy, largely driven by aberrant activation of the
protein kinase B (AKT) survival pathway. Although small-molecule AKT
inhibitors can enhance chemosensitivity, their systemic activity frequently
disrupts normal metabolic processes and causes severe side effects.
Here, we report an “all-in-one” catalytic nanodrug that
integrates a dual-enzyme-mimicking nanozyme (GPMM) with doxorubicin
(Dox) to overcome these limitations. GPMM simultaneously exhibits
peroxidase (POD)-like and phosphatase-like activities, enabling two
synergistic biochemical actions: (i) amplification of reactive oxygen
species (ROS) through tumor-microenvironment-responsive catalytic
conversion of endogenous hydrogen peroxide (H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;), and (ii) depletion of intracellular nicotinamide adenine dinucleotide
(NADH) to weaken antioxidant defenses. This dual modulation induces
persistent oxidative stress and leads to precise inhibition of AKT
phosphorylation, functioning as an effective and safer alternative
to conventional AKT inhibitors. As a result, Dox@GPMM markedly enhances
chemosensitivity and suppresses tumor growth in nonresistant MCF-7
breast cancer models, while the MUC1 aptamer-functionalized formulation
AP-Dox@GPMM effectively reverses Dox resistance in MCF-7-ADR models,
without observable systemic toxicity. RNA-sequencing analysis further
reveals that the nanozyme regulates key genes involved in metabolism,
survival, and AKT-related signaling, thereby reshaping cellular response
to chemotherapy. Collectively, this nanozyme-driven redox strategy
provides a robust and generalizable approach for boosting chemotherapeutic
efficacy while minimizing adverse effects, offering strong translational
potential for overcoming resistance across diverse tumor types.</dc:description>
          <dc:date>2026-09-29T00:00:00Z</dc:date>
          <dc:type>Text</dc:type>
          <dc:type>Journal contribution</dc:type>
          <dc:identifier>10.1021/acsnano.6c12630.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/journal_contribution/Bifunctional_Nanozymes_for_Synergistic_Treatment_by_Boosting_Oxidative_Stress_and_Regulating_the_Protein_Kinase_B_Pathway/34027379</dc:relation>
          <dc:rights>CC BY-NC 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
